The reiteration of an Outperform rating by a reputable analyst like Gregory Renza, coupled with a high price target of $195, suggests a strong confidence in Jazz Pharmaceuticals' future performance. This endorsement is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.